KDR and neoplasm: Bevacizumab functions as a monoclonal antibody designed to target vascular endothelial growth factor A (VEGF-A), blocking its interaction with vascular endothelial growth factor receptor (VEGFR) and inhibiting angiogenesis, a process that supports tumor growth.